Trial Profile

A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Corifollitropin alfa (Primary) ; Chorionic gonadotropin; Follicle stimulating hormones; Follitropin beta; Ganirelix; Progesterone; Progesterone
Indications Female infertility
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ENSURE
Sponsors Organon; Schering-Plough

17 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
03 Jul 2012 Additional location (Denmark) added as reported by European Clinical Trials Database.(Parent trial: EudraCT2006-003811-36).
01 Jul 2009 Results have been presented at the European Society of Human Reproduction and Embryology, according to a Schering-Plough media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com